Searched for
CIPLA SHARE OUTLOOK
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Is India Inc's CSR truly driving systemic change or just shifting funds?Corporate India is entering a new phase of CSR. Spending is expected to cross ₹1.2 lakh crore by 2035. Companies are shifting towards syste...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Q4 earnings, crude oil, FII action among 8 factors to steer D-Street this weekIndian stock markets are set for a busy week. Key events like Q4 earnings announcements for many companies will influence trading. Foreign ...
- Pharma stocks buck market weakness as Dr Reddy's gainsPharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...
- Cipla promoters sell 2.53% stake for around Rs 2,600 crorePromoters of Cipla, including Person Acting in Concert, sold 2.04 crore shares in a block deal worth around Rs 2,600 crore to create liquid...
- Promoter group entities likely to sell 2.5% stake in Cipla worth Rs 2,637 crore via block deals: ReportThe price range of the block is fixed at Rs 1,289-1,357, taking the total deal value to around Rs 2,637 crore.
- Cipla shares gain 6% on upbeat Q4 numbersJefferies has maintained its 'Hold' rating while increasing the price target from ₹1,250 to ₹1,400. "We maintain our Hold rating on the sto...
- Cipla shares surge over 6% post Q4 results. Should you buy or sell?Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period.
- Fundamental Radar | Cipla upgraded to “buy” on 5 major growth tailwinds: Motilal OswalCipla recorded an 8% growth in sales on the back of the launch of the generic version of Revlimid and gained market share in lanreotide, al...
- Buy Cipla, target price Rs 1,090: ICICI DirectICICI Direct has issued a buy call on Cipla with a target price of Rs 1090, higher than the current market price of Rs 914.45. Analysts pro...
- Market Movers: Why Cipla shined and retail investor honeymoon is over?Cipla’s shares surged nearly 4 per cent on a day when the Nifty50 slumped over 2 per cent as investors looked for defensive stocks to hide ...
- Analysts expect Cipla to return up to 30% from here on as India biz gains momentumKotak Securities said the expansion of the Covid portfolio would support near-term earnings while the continued rollout of respiratory fran...
- Dispute settlement gives this stock an edge over peers in pharma packKunal Dhamesha of Emkay Global raised his price target for the stock to Rs 1,000 and sees potential gain of Rs 45 per share from the settle...
- Analysts give a thumbs up to Cipla’s Q2 report card, see 30% upside in the stockJefferies was the most optimistic as it maintained its buy rating on the stock, and raised the target price to Rs 1,024 from Rs 914 earlier.
- Brokerages raise targets on CiplaCipla’s shares hit a record high of Rs 814.45 on Monday before ending at Rs 795.65, up 9.2 per cent from the previous close. Cipla reported...
- Cipla posts 44% rise in Q2 net profit; India sales flatIn the past quarter, Cipla posted Rs 3,452 crore of revenue, compared with Rs 2,767 crore a year earlier.
- Cipla Q1 net profit zooms over two-fold to Rs 651 croreCipla today reported an over two-fold jump in its consolidated net profit to Rs 650.61 crore for the quarter ended June 30, 2015 mainly on ...
- Buy Aurobindo Pharma for Rs 1450-1500 target in 3 weeks: Devang VisariaWith a three weeks' time horizon, we are looking for targets closer to Rs 1,450-1,500 for Aurobindo Pharma.
Load More
